表紙
市場調查報告書

HER2(人類表皮生長因子受體2)抑制劑的全球市場:2019年∼2023年

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 907836
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
HER2(人類表皮生長因子受體2)抑制劑的全球市場:2019年∼2023年 HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年08月14日內容資訊: 英文 130 Pages
簡介

全球HER2(人類表皮生長因子受體2)抑制劑市場上,乳癌及胃癌高的盛行率,最新的認證,乳癌相關意識的高漲等成為成長促進因素,在預測期間內預計將以約9%的年複合成長率擴大。但,Herceptin生物相似藥的引進,替代治療選擇的利用可能性,及HER2抑制劑的副作用等的不穩定要素,可能妨礙在預測期間內HER2抑制劑產業的成長。

本報告提供全球HER2(人類表皮生長因子受體2)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 報告的範圍

  • 序文
  • 序文
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 單劑療法
  • 聯合治療
  • 市場機會:各產品

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 患者支援計劃
  • 乳癌的新診斷法的引進
  • 策略性聯盟

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology, Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31894

About this market

Technavio's HER2 inhibitors market analysis considers sales from both monotherapy and combination therapy. Our analysis also considers the sales of HER2 inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the presence of blockbuster drugs and fewer side-effects will play a significant role in the monotherapy segment to maintain its market position. Also, our global HER2 inhibitors market report looks at factors such as the high prevalence of breast cancer and gastric cancer, recent approvals, and growing awareness about breast cancer. However, uncertainties in the introduction of Herceptin biosimilars, availability of alternative treatment options, and side effects of HER2 inhibitors may hamper the growth of the HER2 inhibitors industry over the forecast period.

Overview

High prevalence of breast cancer and gastric cancer

HER2 regulates cell growth, survival, and differentiation through multiple signal transduction pathways. Owing to the overexpression of HER2, the prevalence of several cancers including breast cancer, gastric and ovarian cancer is increasing. As there is a significant unmet need for effective HER2 inhibitors with fewer side-effects, pharmaceutical companies have significant scope for growth. This will lead to the expansion of the global HER2 inhibitors market at a CAGR of almost 9% during the forecast period.

Patient assistance programs

HER2 inhibitors are available at high costs, making it difficult for patients to purchase them. Thus, pharmaceutical sponsors are providing several patient assistance programs to reduce the cost burden, thus increasing patient adherence to HER2 inhibitors. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global HER2 inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global HER2 inhibitors market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading HER2 inhibitors manufacturers, that include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc.

Also, the HER2 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Patient assistance programs
  • Introduction of new diagnostics for breast cancer
  • Strategic alliances

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology, Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Blockbuster drug sales for last three years
  • Exhibit 22: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Sales of PERJETA for last three years
  • Exhibit 25: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Effect on Herceptin sales after launch of biosimilars
  • Exhibit 45: Examples of available Herceptin biosimilars
  • Exhibit 46: Side effects associated with HER2 inhibitors
  • Exhibit 47: Impact of drivers and challenges
  • Exhibit 48: Approximate cost of HER2 inhibitors
  • Exhibit 49: Examples of recently approved diagnostics for breast cancer
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 56: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 57: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 58: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 59: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 60: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 61: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 62: Merck & Co. Inc. - Vendor overview
  • Exhibit 63: Merck & Co. Inc. - Business segments
  • Exhibit 64: Merck & Co. Inc. - Organizational developments
  • Exhibit 65: Merck & Co. Inc. - Geographic focus
  • Exhibit 66: Merck & Co. Inc. - Segment focus
  • Exhibit 67: Merck & Co. Inc. - Key offerings
  • Exhibit 68: Merck & Co. Inc. - Key customers
  • Exhibit 69: Novartis AG - Vendor overview
  • Exhibit 70: Novartis AG - Business segments
  • Exhibit 71: Novartis AG - Organizational developments
  • Exhibit 72: Novartis AG - Geographic focus
  • Exhibit 73: Novartis AG - Segment focus
  • Exhibit 74: Novartis AG - Key offerings
  • Exhibit 75: Novartis AG - Key customers
  • Exhibit 76: Pfizer Inc. - Vendor overview
  • Exhibit 77: Pfizer Inc. - Business segments
  • Exhibit 78: Pfizer Inc. - Organizational developments
  • Exhibit 79: Pfizer Inc. - Geographic focus
  • Exhibit 80: Pfizer Inc. - Segment focus
  • Exhibit 81: Pfizer Inc. - Key offerings
  • Exhibit 82: Pfizer Inc. - Key customers
  • Exhibit 83: Puma Biotechnology Inc. - Vendor overview
  • Exhibit 84: Puma Biotechnology Inc. - Business segments
  • Exhibit 85: Puma Biotechnology Inc. - Organizational developments
  • Exhibit 86: Puma Biotechnology Inc. - Key offerings
  • Exhibit 87: Puma Biotechnology Inc. - Key customers
  • Exhibit 88: Validation techniques employed for market sizing
  • Exhibit 89: Definition of market positioning of vendors
Back to Top